menu

The Case for Multiplex Testing: Next-Generation Sequencing for NSCLC

Be part of the knowledge.
Register

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free

The Case for Multiplex Testing: Next-Generation Sequencing for NSCLC

ReachMD Healthcare Image
Restart
Resume
Read full article
Choose a format
Media formats available:
A pre-test is required to view this content.
A pre-survey is required to view this content.
Details
Presenters
Comments
  • Sponsored by

  • Overview

    How is multiplex testing with next-generation sequencing different from other diagnostic tools? Dr. Balazs Halmos, the Director of Thoracic Oncology and Clinical Cancer Genomics at Montefiore Medical Park at Eastchester in the Bronx, New York, discusses how this type of testing can contribute to improved health outcomes and tailored treatment regimens for patients with non-small cell lung cancer, or NSCLC.

Facebook Comments

Recommended
Details
Presenters
Comments
  • Sponsored by

  • Overview

    How is multiplex testing with next-generation sequencing different from other diagnostic tools? Dr. Balazs Halmos, the Director of Thoracic Oncology and Clinical Cancer Genomics at Montefiore Medical Park at Eastchester in the Bronx, New York, discusses how this type of testing can contribute to improved health outcomes and tailored treatment regimens for patients with non-small cell lung cancer, or NSCLC.

Facebook Comments

Schedule30 Nov 2021
Webpack App